Oncology
Mosaic Therapeutics in-licenses clinical oncology programmes from Astex Pharma
April 25, 2025Clinical Trial Services, Industry Associations, Mergers and Acquisitions, Research and Development Astex pharmaceuticals, Mosaic Therapeutics, Oncology, clinical trial
Two clinical-stage oncology programmes from Astex Pharmaceuticals have been announced by Mosaic Therapeutics, allowing it to develop targeted oncology drug …
Philippe Masset appointed to Vect-Horus board of directors
April 25, 2025Research and Development Oncology, Vect-Horus, appointment, board of directors, imaging agents
Vect-Horus has announced the appointment of Philippe Masset to the company’s board of directors. This contributes to a series of …
Mursla Bio’s platform for surveillance of liver cancer receives FDA approval
April 24, 2025Industry Associations, Research and Development BDD, FDA, Mursla Bio, Oncology, hepatocellular carcinoma (HCC), liver disease
The US Food and Drug Administration (FDA) has granted Breakthrough Device Designation (BDD) to EvoLiver, Mursla Bio’s surveillance platform for …
ViroCell and UCL launch trial to treat childhood leukaemia relapse
April 24, 2025Research and Development Oncology, UCL, ViroCell, acute lymphoblastic leukaemia, cell therapy, clinical trial, leukaemia
ViroCell Biologics has manufactured a GMP-grade lentiviral vector for a University College London (UCL) clinical trial aimed at tackling relapse …
Dual immunotherapy for bowel cancer now available under NHS
April 23, 2025Research and Development Bristol Myer Squibb, MHRA, NICE, Oncology, bowel cancer, colorectal cancer, immunotherapy
Dual immunotherapy, a combination of Opdivo (nivolumab) and Yervoy (ipilimumab), has been granted extension in the UK by the Medicines …
Johnson & Johnson announces successful results from trial for myeloma treatment
April 16, 2025Research and Development Johnson & Johnson, Oncology, myeloma, pharma, trial
Global healthcare company, Johnson & Johnson, announced that analysis of its Darzalex (daratumumab) therapy showed significantly longer progression-free survival (PFS) …
AAX Biotech aims to enhance growth with two new appointments
April 10, 2025Business Development, Recruitment, Research and Development AAX Biotech, Immunology, Oncology, R&D development, antibody therapeutics, business development
AAX Biotech has appointed Ionut Gabriel Dumitru (pictured left) as senior scientist and Kushal Sejwal (pictured right) as business developer, …
Infinitopes launches first-in-human trial of vaccine targeting oesophageal cancer
April 9, 2025Research and Development Infinitopes, Oncology, biotech, oesophageal cancer, oncology
The cancer biotech company Infinitopes has gained approval by the UK Medicines and Healthcare products Regulatory Agency (MHRA) to evaluate …
European consortium launches project to advance alpha-emitting radiotherapies
April 7, 2025Research and Development Akiram Therapeutics, European Consortium, Oncology, PreTT, TetraKit Technologies, radiotherapy
A new European research initiative PRE-CISE has been launched with the aim of developing next-generation targeted alpha-therapies for cancer treatment. …
Bristol Myers Squibb receives positive CHMP opinion for Opdivo treatment
April 4, 2025Research and Development CHMP, Oncology, bristol myers squibb, immunotherapy, lung cancer, opdivo
Bristol Myers Squibb (BMS) has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for …
Curium Pharma announces acquisition of Monrol
April 3, 2025Manufacturing and Production, Research and Development Curium Pharma, Monrol, Oncology, acquisition, nuclear medicine, radiopharmaceutical products
Curium Pharma, a nuclear medicine company, has acquired Eczacıbaşı-Monrol Nuclear Products (Monrol), a nuclear medicine player. With facilities across Europe …
Corcept’s relacorilant trial in patients with platinum-resistant ovarian cancer meets primary endpoint
April 1, 2025Research and Development Corcept Therapeutics, Oncology, ovarian cancer, research and development
Corcept Therapeutics announced that relacorilant plus nab-paclitaxel met its primary endpoint of improved progression-free survival in ROSELLA, the company’s phase …
Secarna Pharmaceuticals to announce positive new data at cancer research conference
April 1, 2025Research and Development Oncology, Secarna Pharmaceuticals, oncology, research and development
Secarna Pharmaceuticals will present new preclinical data with its lead programme SECN-15 at the American Association for Cancer Research (AACR) …
Shane Olwill appointed as chief development officer at Asgard Therapeutics
March 28, 2025Business Services, Clinical Research Asgard Therapeutics, CDO, Oncology, appointment, immunology
Asgard Therapeutics has announced the appointment of Shane Olwill as chief development officer (CDO). The biotech company develops in vivo …
Pierre Fabre announces investments and partnerships in lung cancer research
March 27, 2025Research and Development Oncology, Pierre Fabre Laboratories, lung cancer treatment, oncology
Pierre Fabre Laboratories has announced investment and partnership plans to improve the lives of lung cancer patients with unmet needs. …
Latest content
FibroFind appoints Lee Borthwick as CEO
